Clinical Trials
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8703
Evaluation of Vinblastine and High-Dose Cis-Platinum in the Treatment of Advanced Non-Small Cell Lung Cancer
Activated
09-01-1987
Closed
06-01-1989
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8625
Weekly Cis-Platinum-Based Induction for Extensive Non-Small Lung Cancer, with Cis-Platinum + VP-16 Consolidation
Activated
09-01-1987
Closed
01-15-1988
Closed
Phase
Accrual
90%
Published
SWOG Clinical Trial Number
SWOG-8704
Neoadjuvant Methotrexate, Cisplatin and Vinblastine (MCV) Followed by Concomitant Cisplatin/Radiotherapy for Unresectable Localized Bladder Cancer Patients
Research Committee(s)
Genitourinary Cancer
Activated
09-01-1987
Closed
08-15-1991
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8605
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8623
A Phase II Trial of Trimetrexate in Untreated Advanced Gastric Carcinoma
Activated
08-15-1987
Closed
01-01-1989
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)
Trial of Cystectomy Alone Versus Neoadjuvant M-VAC +Cystectomy in Patients with Locally Advanced Bladder Cancer
Research Committee(s)
Genitourinary Cancer
Activated
08-01-1987
Closed
07-01-1998
Closed
Phase
Accrual
77%
Published
SWOG Clinical Trial Number
SWOG-8692 (INT-0075)
Therapy In Premenopausal Women with Advanced, ER Positive or PgR Positive Breast Cancer: Surgical Oophorectomy vs. the LH-RH Analog, Zoladex
Research Committee(s)
Breast Cancer
Activated
08-01-1987
Closed
07-15-1995
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8712
A Phase ll Trial of Trimetrexate in the Treatment of Hepatoma
Activated
07-15-1987
Closed
01-01-1989
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8632
Evaluation of Echinomycin In Central Nervous System Tumors
Activated
06-01-1987
Closed
03-01-1989
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8707
Evaluation of Recombinant Gamma Interferon In Renal Cell Carcinoma
Activated
06-01-1987
Closed
01-01-1988
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8642
Recombinant Human Interferon-Gamma for the Adjuvant Treatment of High Risk Malignant Melanoma After Surgical Excision of the Primary Lesion
Research Committee(s)
Melanoma
Activated
06-01-1987
Closed
05-15-1990
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8630
Phase II Study of Recombinant DNA Gamma Interferon in Advanced Colorectal Cancer
Activated
05-15-1987
Closed
11-15-1988
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8626
Phase II Study of Recominbant DNA Gamma Interferon in Advanced Cancer of the Pancreas
Activated
05-15-1987
Closed
11-15-1988
Closed
Phase
Accrual
99%
Published
SWOG Clinical Trial Number
SWOG-8616 (INT-0072)
Intergroup Phase lll Randomized Study of Doxorubicin and Dacarbazine With or Without Ifosfamide and Mesna in Advanced Soft Tissue and Bone Sarcomas
Research Committee(s)
Sarcoma
Activated
05-15-1987
Closed
07-01-1991
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8750
Pilot Study to Examine Cytogenetic Abnormalities in Patients with Acute Leukemia, Ancillary
Activated
04-15-1987
Closed
10-15-1991
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8617
Evaluation of Interleukin 2 (rIL-2) in Metastatic Renal Cell Carcinoma
Activated
03-15-1987
Closed
08-15-1988
Closed
Phase
Accrual
2%
SWOG Clinical Trial Number
SWOG-8693 (INT-0058)
Adjuvant Therapy of Primary Osteosarcoma: A Phase II Randomized Intergroup Study
Activated
03-01-1987
Closed
06-15-1990
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8608
Mitoxantrone Plus Cis-Platinum in Patients with Advanced Breast Cancer
Activated
02-16-1987
Closed
08-01-1989
Closed
Phase
SWOG Clinical Trial Number
SWOG-8629
Adjuvant Therapy with Adriamycin plus Cisplatin for Endometrial Sarcomas at High Risk of Recurrance
Activated
02-01-1987
Closed
12-15-1988
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8624
A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma; Comparison of (1) VMCP/VBAP to VAD or VMCPP/VBAPP for Induction; (2) Alpha-2b Interferon or No Therapy for Maintenance; and 3) Alpha-2b Interferon + Dexamethasone for Incomplete or Non-Responders; and (4) VAD Plus Verapamil For Incomplete or Non-Responders on VAD
Research Committee(s)
Myeloma
Activated
02-01-1987
Closed
10-01-1990